MedTrace Logo

A Study of SYHA1805 in Healthy Subjects

NCT04977570 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-07-27

No results posted yet for this study

Summary

This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose of SYHA1805.

Conditions

  • Healthy Subjects

Interventions

DRUG

SYHA1805 tablets

Oral tablets of SYHA1805 with three pre-designed doses

DRUG

Placebo

Oral tablets of placebo with matching doses

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kun Lou, master · CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-05-31
Completion
2022-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04977570 on ClinicalTrials.gov